This case presentation outlines the importance of effective antiemetic protection in the setting of moderately emetogenic cancer chemotherapy and highlights the challenges in achieving that goal. Medscape Hematology-Oncology
A multicenter trial has validated the predictive value of Ki67 in identifying patients with worse outcomes, and now an ongoing trial is investigating whether this can improve outcomes. Medscape Medical News
Many clinical trials of targeted therapies have produced disappointing results, but biomarker identification and other strategies outlined in this article should help to improve outcomes. Nature Reviews Clinical Oncology
Dr. Mark Kris highlights the therapeutic benefits -- and toxicities -- associated with bevacizumab use in patients with non-small cell lung cancer. Medscape Hematology-Oncology
The procedure offers an option for patients who cannot undergo surgery but is also being chosen by patients as an alternative to surgery. Medscape Medical News